Viridian LLC Amends Stake in Dianthus Therapeutics
Ticker: DNTH · Form: SC 13D/A · Filed: Sep 12, 2024 · CIK: 1690585
| Field | Detail |
|---|---|
| Company | Dianthus Therapeutics, INC. /De/ (DNTH) |
| Form Type | SC 13D/A |
| Filed Date | Sep 12, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 13D-filing, ownership-change, biotech
TL;DR
Viridian LLC just updated its 13D filing for Dianthus Therapeutics. Keep an eye on this one.
AI Summary
Viridian, LLC, a significant shareholder, filed an amendment to its Schedule 13D on September 12, 2024, regarding its holdings in Dianthus Therapeutics, Inc. The filing indicates a change in the beneficial ownership of Dianthus Therapeutics, Inc. common stock, though specific new ownership percentages or dollar amounts are not detailed in this excerpt. This amendment follows a previous filing and suggests ongoing activity or adjustments in Viridian's investment strategy concerning Dianthus Therapeutics.
Why It Matters
This filing signals a potential shift in the ownership structure or strategic interest of a major shareholder in Dianthus Therapeutics, which could impact the company's stock performance and future direction.
Risk Assessment
Risk Level: medium — Schedule 13D filings often indicate significant investor activity, which can lead to price volatility and strategic changes for the company.
Key Numbers
- 0001690585 — Dianthus Therapeutics CIK (Unique identifier for Dianthus Therapeutics)
- 0001761506 — Viridian, LLC CIK (Unique identifier for Viridian, LLC)
- 20240912 — Filing Date (Date the amendment was filed)
Key Players & Entities
- Viridian, LLC (company) — Filing party
- Dianthus Therapeutics, Inc. (company) — Subject company
- Ryan A. Murr (person) — Authorized contact for notices
- Gibson, Dunn & Crutcher LLP (company) — Legal counsel
- Magenta Therapeutics, Inc. (company) — Former company name
FAQ
What specific changes in beneficial ownership are reported in this SC 13D/A filing?
The filing is an amendment to a Schedule 13D, indicating a change in beneficial ownership, but the specific details of the change (e.g., new percentage, number of shares) are not provided in this excerpt.
Who is Viridian, LLC and what is their relationship to Dianthus Therapeutics?
Viridian, LLC is the entity filing the Schedule 13D/A, indicating it is a significant shareholder in Dianthus Therapeutics, Inc.
When was this amendment filed with the SEC?
This amendment (SC 13D/A) was filed on September 12, 2024.
What was Dianthus Therapeutics, Inc. formerly known as?
Dianthus Therapeutics, Inc. was formerly known as Magenta Therapeutics, Inc., with a name change date of November 21, 2016.
What is the business address of Viridian, LLC?
The business address for Viridian, LLC is 2001 Market Street, Suite 2500, Philadelphia, PA 19103.
Filing Stats: 711 words · 3 min read · ~2 pages · Grade level 12.3 · Accepted 2024-09-12 20:45:53
Key Financial Figures
- $0.001 — INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securiti
Filing Documents
- tm2423966d1_sc13d.htm (SC 13D/A) — 26KB
- 0001104659-24-099432.txt ( ) — 28KB
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of our knowledge and belief, we certify that the information set forth in this Statement as of September 12, 2024. VIRIDIAN, LLC By: /s/ Peter Harwin Peter Harwin Member and Co-Manager